The L1210 assay for immune complexes: application in cancer patients and correlation with disease progress.
Immune complexes (ICs) were determined by the non-complement-dependent L1210 radioimmune assay on 132 serum samples collected from 53 patients with a variety of cancers. Both the mean IC levels and frequency of positive tests were significantly greater in cancer patients (mean = 96 +/- 100 microgram/ml, 46% positive) than in a control group of 67 normal healthy blood donors (mean = 39 +/- 15, 3% positive). When cancer patients were assorted into groups by disease progress, those with large or progressing tumors had significantly higher mean values (136 +/- 129) and frequency of positives (75%) than those with small or regressing tumors (58 +/- 18, 22% positive). In lung cancer patients, IC levels showed a strong inverse correlation (rs = -0.903) with survival time in patients who died, and appeared to be a better prognostic indicator than performance status (Karnofsky scale) at time of diagnosis. Serial IC measurements taken on several patients showed a decrease in levels concomitant with a favorable response to cytoreductive therapy, sustained normal levels during periods of prolonged remission, and a rise to elevated levels with (and sometimes preceding) documentation of new metastases.
D000818:Animals; D000936:Antigen-Antibody Complex; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002460:Cell Line; D003110:Colonic Neoplasms / Q000276:immunology; D005260:Female; D006801:Humans; D007939:Leukemia L1210 / Q000276:immunology*; D008175:Lung Neoplasms / Q000276:immunology; D008297:Male; D009369:Neoplasms / Q000276:immunology*; D011379:Prognosis; D011863:Radioimmunoassay; D012075:Remission, Spontaneous
D000936:Antigen-Antibody Complex; D000970:Antineoplastic Agents